Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

View source ↗

Summary

An observational study evaluating Rituximab (Rituxan/MabThera) in seropositive rheumatoid arthritis patients who did not respond to or could not tolerate a sing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituxan/MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2016-04-21